{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:45:59Z","timestamp":1793785559496,"version":"4.6.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T00:00:00Z","timestamp":1784678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The GO39775 study was sponsored by F. Hoffmann-La Roche Ltd\/Genentech"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41591-026-04522-3","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T09:01:46Z","timestamp":1784710906000},"page":"2909-2917","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["FcRH5\u00d7CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial"],"prefix":"10.1038","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0939-3843","authenticated-orcid":false,"given":"Adam D.","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7952-6352","authenticated-orcid":false,"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9321-702X","authenticated-orcid":false,"given":"Alexander","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob P.","family":"Laubach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8596-7058","authenticated-orcid":false,"given":"Sheeba K.","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4555-6582","authenticated-orcid":false,"given":"Simon J.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5362-2469","authenticated-orcid":false,"given":"Luciano J.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Forsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4362-0376","authenticated-orcid":false,"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayan","family":"Kaedbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7353-7034","authenticated-orcid":false,"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Rodriguez-Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2390-1218","authenticated-orcid":false,"given":"Maria-Victoria","family":"Mateos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulika","family":"Tyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divya","family":"Samineni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rin","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Voleak","family":"Choeurng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihunt","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amrita","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,22]]},"reference":[{"key":"4522_CR1","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","volume":"33","author":"UH Gandhi","year":"2019","unstructured":"Gandhi, U. H. et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia 33, 2266\u20132275 (2019).","journal-title":"Leukemia"},{"key":"4522_CR2","doi-asserted-by":"publisher","first-page":"2554","DOI":"10.1038\/s41375-024-02404-6","volume":"38","author":"M-V Mateos","year":"2024","unstructured":"Mateos, M.-V. et al. LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed\/refractory multiple myeloma\u20142-year follow-up (final analysis). Leukemia 38, 2554\u20132560 (2024).","journal-title":"Leukemia"},{"key":"4522_CR3","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja, J. G. et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398, 314\u2013324 (2021).","journal-title":"Lancet"},{"key":"4522_CR4","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","volume":"387","author":"A Chari","year":"2022","unstructured":"Chari, A. et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N. Engl. J. Med. 387, 2232\u20132244 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4522_CR5","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin, A. M. et al. Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat. Med. 29, 2259\u20132267 (2023).","journal-title":"Nat. Med."},{"key":"4522_CR6","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495\u2013505 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4522_CR7","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"4522_CR8","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"H Lee","year":"2023","unstructured":"Lee, H. et al. Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. Nat. Med. 29, 2295\u20132306 (2023).","journal-title":"Nat. Med."},{"key":"4522_CR9","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1182\/blood.2022015956","volume":"140","author":"N Philipp","year":"2022","unstructured":"Philipp, N. et al. T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals. Blood 140, 1104\u20131118 (2022).","journal-title":"Blood"},{"key":"4522_CR10","doi-asserted-by":"publisher","first-page":"3006","DOI":"10.1158\/1078-0432.CCR-23-3333","volume":"30","author":"CPM Verkleij","year":"2024","unstructured":"Verkleij, C. P. M. et al. T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma. Clin. Cancer Res. 30, 3006\u20133022 (2024).","journal-title":"Clin. Cancer Res."},{"key":"4522_CR11","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/1535-7163.MCT-12-0087","volume":"11","author":"K Elkins","year":"2012","unstructured":"Elkins, K. et al. FcRL5 as a target of antibody\u2013drug conjugates for the treatment of multiple myeloma. Mol. Cancer Ther. 11, 2222\u20132232 (2012).","journal-title":"Mol. Cancer Ther."},{"key":"4522_CR12","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/sj.leu.2404445","volume":"21","author":"T Ise","year":"2007","unstructured":"Ise, T. et al. Elevation of soluble CD307 (IRTA2\/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia 21, 169\u2013174 (2007).","journal-title":"Leukemia"},{"key":"4522_CR13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","volume":"18","author":"AG Polson","year":"2006","unstructured":"Polson, A. G. et al. Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int. Immunol. 18, 1363\u20131373 (2006).","journal-title":"Int. Immunol."},{"key":"4522_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39395-4","volume":"14","author":"D Jiang","year":"2023","unstructured":"Jiang, D. et al. Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. Nat. Commun. 14, 3642 (2023).","journal-title":"Nat. Commun."},{"key":"4522_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","volume":"31","author":"J Li","year":"2017","unstructured":"Li, J. et al. Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing. Cancer Cell 31, 383\u2013395 (2017).","journal-title":"Cancer Cell"},{"key":"4522_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0178-8","volume":"9","author":"AK Stewart","year":"2019","unstructured":"Stewart, A. K. et al. Phase I study of the anti-FcRH5 antibody\u2013drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. Blood Cancer J. 9, 17 (2019).","journal-title":"Blood Cancer J."},{"key":"4522_CR17","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346 (2016).","journal-title":"Lancet Oncol."},{"key":"4522_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee, D. W. et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124, 188\u2013195 (2014).","journal-title":"Blood"},{"key":"4522_CR19","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","volume":"387","author":"S Mailankody","year":"2022","unstructured":"Mailankody, S. et al. GPRC5D-targeted CAR T cells for myeloma. N. Engl. J. Med. 387, 1196\u20131206 (2022).","journal-title":"N. Engl. J. Med."},{"key":"4522_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"CJ Ferreri","year":"2023","unstructured":"Ferreri, C. J. et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 13, 117 (2023).","journal-title":"Blood Cancer J."},{"key":"4522_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01259-z","volume":"15","author":"CR Tan","year":"2025","unstructured":"Tan, C. R. et al. Real-world evaluation of teclistamab for the treatment of relapsed\/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study. Blood Cancer J. 15, 53 (2025).","journal-title":"Blood Cancer J."},{"key":"4522_CR22","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"C Touzeau","year":"2024","unstructured":"Touzeau, C. et al. Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies. Blood 144, 2375\u20132388 (2024).","journal-title":"Blood"},{"key":"4522_CR23","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"AD Cohen","year":"2023","unstructured":"Cohen, A. D. et al. Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 141, 219\u2013230 (2023).","journal-title":"Blood"},{"key":"4522_CR24","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1182\/blood-2024-203409","volume":"144","author":"D Dima","year":"2024","unstructured":"Dima, D. et al. Outcomes of teclistamab (Tec) in patients with relapsed\/refractory multiple myeloma (RRMM) with prior exposure to BCMA-directed therapy (BCMA-DT): a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood 144, 897 (2024).","journal-title":"Blood"},{"key":"4522_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"N Raje","year":"2023","unstructured":"Raje, N. et al. Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood Cancer J. 13, 116 (2023).","journal-title":"Blood Cancer J."},{"key":"4522_CR26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1182\/blood-2025-699","volume":"146","author":"A Cohen","year":"2025","unstructured":"Cohen, A. et al. Phase 2 study of cevostamab consolidation following BCMA CAR T cell therapy: preliminary safety, efficacy, and correlative data from the \u201cSTEM\u201d (Sequential T Cell-Engagement for Myeloma) trial. Blood 146, 699 (2025).","journal-title":"Blood"},{"key":"4522_CR27","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1182\/blood-2025-252","volume":"146","author":"S Harrison","year":"2025","unstructured":"Harrison, S. et al. Tumor clearance, T-cell fitness, and minimal residual disease (MRD) outcomes in patients with relapsed\/refractory multiple myeloma (RRMM) treated with cevostamab plus pomalidomide and dexamethasone: biomarker analyses from CAMMA 1 Arm B. Blood 146, 252 (2025).","journal-title":"Blood"},{"key":"4522_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/ajh.20398","volume":"80","author":"M Okano","year":"2005","unstructured":"Okano, M. et al. Proposed guidelines for diagnosing chronic active Epstein\u2013Barr virus infection. Am. J. Hematol. 80, 64\u201369 (2005).","journal-title":"Am. J. Hematol."},{"key":"4522_CR29","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 (National Cancer Institute, 2009); https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v4.pdf"},{"key":"4522_CR30","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transplant 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transplant"}],"updated-by":[{"DOI":"10.1038\/s41591-026-04757-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:00:00Z","timestamp":1792454400000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04522-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04522-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T05:38:22Z","timestamp":1792561102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-026-04522-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,22]]},"references-count":30,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4522"],"URL":"https:\/\/doi.org\/10.1038\/s41591-026-04522-3","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,22]]},"assertion":[{"value":"3 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-026-04757-0","URL":"https:\/\/doi.org\/10.1038\/s41591-026-04757-0","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.D.C. discloses consultancy (AbbVie, Arcellx, AstraZeneca, BMS, Caribou, Genentech\/Roche, GSK, iTeos, Janssen, Kite, Legend, Moderna, Pfizer, Prothena, Regeneron, Sanofi), research funding (Genentech\/Roche, GSK, Janssen, Novartis), patents and royalties (Novartis) and advisory committees (Ichnos, Novartis). J.R. discloses consultancy (AbbVie, BMS, Forus, Genentech, Janssen, Karyopharm, Kite\/Arcellx, Menarini, Pfizer, Regeneron, Sanofi, Takeda, UB Therapeutics) and speaker\u2019s bureau (Adaptive Biotechnologies, BMS, Janssen, Pfizer, Sanofi). S.T. discloses consultancy (GSK), research funding (BMS, Genentech, GSK, Janssen, K36 Therapeutics, Pfizer, Roche), honoraria (AstraZeneca, GSK, Janssen) and advisory committees (AstraZeneca, BMS, GSK, Janssen, Kite\/Arcellx, Pfizer, Roche, Sanofi). A.L. discloses employment (Memorial Sloan Kettering Cancer Center), consultancy (Arcellx, Janssen, Pfizer), honoraria (Pfizer) and patents and royalties (Serametrix). J.P.L. has no conflicts of interest or relevant competing interests. S.K.T. discloses research funding (AbbVie, Ascentage Pharma, BMS, Cellectar Biosciences, Genentech, Janssen, Sanofi). S.J.H. discloses research funding (Johnson & Johnson), honoraria (Celgene, Janssen, Johnson & Johnson, Kite\/Gilead, Novartis), advisory committees (Celgene, Haemalogix, Janssen, Kite\/Gilead, Novartis) and other interests (MSAG chair Myeloma Australia). L.J.C. discloses consultancy (AbbVie, Amgen, AstraZeneca, BMS, Caribou, Genentech, Johnson & Johnson, Pfizer, Sanofi), research funding (AbbVie, Amgen, AstraZeneca, BMS, Caribou, Genentech, Johnson & Johnson) and honoraria (AbbVie, Adaptive Biotechnologies, Amgen, AstraZeneca, BMS, Caribou, Genentech, Johnson & Johnson, Pfizer, Sanofi). A.S. discloses consultancy (BMS, Celltrion, Haemalogix, Janssen, Rheumagen), research funding (AbbVie, Antengene, Haemalogix, Janssen), honoraria (AbbVie, Antengene, BMS, Haemalogix, Janssen, Pfizer, Roche, Sanofi, Thermo Fisher), advisory committees (Antengene, BMS, Haemalogix, Janssen, Pfizer, Roche, Sanofi) and speaker\u2019s bureau (BMS, Janssen, Pfizer, Sanofi, Thermo Fisher). R.F. discloses consultancy (AbbVie, Adaptive, Amgen, Apple, BMS\/Celgene, GSK, Janssen, Karyopharm, Pfizer, RA Capital, Regeneron, Sanofi), equity (Antengene), patents and royalties (FISH in MM), and advisory committees (Caris Life Sciences). P.A.F. discloses consultancy (AbbVie, BMS, GSK, Legend, Pfizer, Sanofi), research funding (Johnson & Johnson), advisory committees (Johnson & Johnson, Pathos) and speaker\u2019s bureau (Sanofi). J.G.B. discloses consultancy (AstraZeneca, BMS, Galapagos, Johnson & Johnson, Karyopharm, Kite, Kyowa Kirin, Pfizer, Regeneron, Roche, Sebia), research funding (AstraZeneca, BMS, C4 Therapeutics, Caribou Biosciences, CARsgen, Cartesian Therapeutics, Genentech, Gracell, GSK, Ichnos Sciences, Johnson & Johnson, Juno Therapeutics, K36 Therapeutics, Karyopharm, Kite, Moderna, Pfizer, Regeneron, Roche, Sanofi) and honoraria (Janssen). R.K. discloses research funding (Pfizer), honoraria (Johnson & Johnson, Pfizer, Sanofi) and advisory committees (Forus, GSK, Johnson & Johnson, Pfizer, Sanofi). N.J.B. discloses consultancy (AbbVie, BMS, Genentech, Johnson & Johnson, Pfizer, Roche, Sanofi), honoraria (AbbVie, BMS, Genentech, Johnson & Johnson, Pfizer, Roche, Sanofi) and advisory committees (AbbVie, BMS, Genentech, Johnson & Johnson, Pfizer, Roche, Sanofi). P.R.-O. discloses consultancy (AbbVie, AstraZeneca, BMS, H3 Biomedicine, GSK, Johnson & Johnson, Menarini Stemline, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi), research funding (Pfizer), honoraria (BMS, GSK, Johnson & Johnson, Pfizer), advisory committees (BMS, Johnson & Johnson, Regeneron) and other interests (Pfizer). M.-V.M. discloses consultancy (Amgen, Johnson & Johnson, Kite, Menarini Stemline, Roche) and honoraria (Amgen, BMS, GSK, Johnson & Johnson, Kite, Menarini Stemline, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi). T.T. discloses employment (Roche\/Genentech) and equity (Gilead, Roche\/Genentech). D.S. discloses employment (Roche\/Genentech) and equity (Roche\/Genentech). W.L. discloses employment (Roche\/Genentech). R.N. discloses employment (Roche\/Genentech) and equity (Roche\/Genentech). V.C. discloses employment (Roche\/Genentech). C.W. discloses past employment (Roche\/Genentech). J.C. discloses past employment (Roche\/Genentech) and equity (Roche\/Genentech). A.K. discloses consultancy (AbbVie, Adaptive, Arcellx, BMS, GSK, Janssen, Roche, Sanofi), equity (Arcellx, BMX) and advisory committees (Johnson & Johnson, Pfizer).","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}